Abstract
Considering drug therapy for pregnant women, it is certain that almost all chemical compounds in use as therapeutic agents pass from the maternal to the fetal circulation through the placenta. These drugs can have a wide range of harmful effects on the fetus and neonate. The effects of some of the substances for which we have data reflecting a deleterious effect are listed.
It is now generally accepted that the developing fetus may be adversely affected by exposure to drugs and environmental chemicals. It is suggested that, in the future, more caution be exercised in using drugs during pregnancy and that any therapy given to the mother during gestation be recorded in detail in both obstetric and pediatric histories.
It is possible that the mother may not have a serious or long-lasting problem after using drugs. But the same is not always true for a fetus. Drug-using mothers often give birth to "drug babies," who go on to have a whole host of developmental problems.
Traditionally, the teratogenic effects of drugs have been noted as anatomical malformations. It is clear that these are related to dose and time and that the fetus is at a greater risk during the first 3 months of gestation. The purpose of this study is to raise the concept of a little known, but potentially serious, health hazard in children and adults. This refers to the ability of perinatally consumed drugs and food additives and nonprescription alternative agents to produce subtle biochemical defects that are undetectable or unrecognized in the neonate but that are expressed years, even decades, after birth.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsFurther Reading
Patel DA, Patel AR. Clorazepate & congenital malformations. JAMA. 1980;244(2):135–6.
Yaffe SJ. Drugs in pregnancy & lactation. London, UK: Elsevier; 2005.
Shepard TH. Catalog of teratologic agents. 6th ed. The Johns Hopkins University Press. Philaldelphia, USA: Lippincott Wilinams Wilkins 1989. ISBN 0: 0801838363 / ISBN 13: 9780801838361
Game E, Bergman U. Benzodiazepine use in pregnancy and major malformations or oral clefts. BMJ. 1999;319:918.
Product information: Prozac. Dista Products; 2000. NDC Code(s): 0777-3104-02, 0777-3105-02, 0777-3105-07, 0777-3105-30
Organisation of teratology information specialists. http://www.teratology.org/
Shuey DL, Sadler TW, Lauder JM. Serotonin as a regulator of craniofacial morphogenesis. Teratology. 1992;46:367–78.
Product Information, GSK; 2004. https://www.gsk.com/media/279898/annual-report-2004.pdf
Somers GF. Thalidomide and congenital abnormalities. Proc R Soc Med. 1965;58:491–2; Lancet 1962;1:912–3.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer India
About this chapter
Cite this chapter
Pardeshi, R., Mane, A. (2016). Drug-Induced Serious Maternal and Fetal Complications in Pregnancy. In: Gandhi, A., Malhotra, N., Malhotra, J., Gupta, N., Bora, N. (eds) Principles of Critical Care in Obstetrics. Springer, New Delhi. https://doi.org/10.1007/978-81-322-2686-4_34
Download citation
DOI: https://doi.org/10.1007/978-81-322-2686-4_34
Published:
Publisher Name: Springer, New Delhi
Print ISBN: 978-81-322-2684-0
Online ISBN: 978-81-322-2686-4
eBook Packages: MedicineMedicine (R0)